GLP-1 receptor agonists cause serious gastrointestinal and biliary adverse events.
- Current status
- EstablishedEvidence stable · Gastrointestinal
- Why
- Gallbladder/biliary disease is increased in a meta-analysis of 76 RCTs (RR 1.37), more so in trials conducted for weight loss (RR 2.29) and at higher doses (RR 1.56), with no significant increase at lower doses. The VA atlas (observational, veterans with diabetes) adds gastrointestinal disorder and drug-induced pancreatitis signals. A claims cohort reporting pancreatitis, gastroparesis and bowel obstruction versus bupropion-naltrexone could not be checked: its research letter was not retrieved, so its figures are not used here.
- What would change it
- Not applicable for the established components; pancreatitis and obstruction estimates need larger randomized confirmation.
- Linked studies
- 3 · 2 supports · 1 consistent, but doesn't test the claim
- Last updated
- Oct 19, 2026
The status is the collection's own judgment on its assessment scale, not a GRADE certainty rating and not medical advice.
The evidence, sorted by what it shows
Supports (2)
- Mapping the effectiveness and risks of GLP-1 receptor agonistsRetrospective cohort · 2025 · Study tier 3 · Different population · Mixed
VA atlas: GI disorders, drug-induced pancreatitis increased.
- Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical TrialsMeta-analysis · 2022 · Study tier 1 · Different population · Harm direction
Meta-analysis of 76 RCTs: GLP-1 RAs increased gallbladder or biliary disease (RR 1.37), more in weight-loss trials (RR 2.29), at higher doses (RR 1.56) and with longer use (RR 1.40), with no significant increase at lower doses (RR 0.99) or shorter use (RR 0.79); severity is not graded in the abstract.
Consistent, but doesn't test the claim (1)
- Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesRandomized trial · 2023 · Study tier 1 · Different population · Benefit · Industry funded
SELECT trial in adults with cardiovascular disease and overweight or obesity without diabetes: adverse events leading to permanent discontinuation occurred in 16.6% on semaglutide vs 8.2% on placebo; the abstract does not report serious GI or biliary event rates.
How this assessment has changed
- EstablishedOct 19, 2026 · Evidence stable
Owner decision 2026-10-18 on IN-061 (claims audit): recommended options accepted (IN-061.32). Status unchanged; rationale corrected to match the audited links.
- EstablishedSep 13, 2026 · Evidence stable
initial curated status